Patients deserve swift, science-based access to lifesaving and life-enhancing innovations. We cannot afford to let political posturing stand in the way of patient health.
In recent months, the FDA has undergone sweeping changes from the current administration. While reforming a bloated and outdated regulatory structure is long overdue, the method matters. The dismissal of approximately 3,500 FDA employees and the ideological leadership of Health and Human Services Secretary RFK Jr. have disrupted the very engine of medical progress.
In our upcoming Podcast Series, we expose how sweeping political decisions are stalling innovation, delaying life-saving treatments, and putting millions at risk.
We’ll break down what’s really happening inside the FDA, why reform must be science-first—not politics-led—and what’s at stake for patients, biotech, and the future of healthcare.
Stay tuned. The consequences are real.
Clinical trials are stalled. Life-saving treatments are delayed. Patients are left waiting.
We strongly support a reformed FDA that is faster, more transparent, and driven by scientific rigor — not political ideology. But gutting regulatory capacity without a clear, evidence-based plan has real-world consequences for millions of Americans who rely on timely access to breakthrough medications, cutting-edge therapies, and biotech innovation.
that evaluates innovation on merit, not on ideology.
regulatory pathways that prioritize patients over politics.
to ensure timely approvals and oversight.
without paralysis because reform shouldn’t mean retreat or delays for patients.
712 H St NE PMB 94982
Washington, DC 20002
Rond Point Schuman 6, Box 5 Brussels, 1040, Belgium
Golden Cross House, 8 Duncannon Street
London, WC2N 4JF, UK
Block D, Platinum Sentral, Jalan Stesen Sentral 2, Level 3 - 5 Kuala Lumpur, 50470, Malaysia
170 Laurier Ave W, Suite 718, Ottawa, Ontario K1P 5V5
© COPYRIGHT 2025, CONSUMER CHOICE CENTER
